Literature DB >> 19782276

Fulminant fatal cardiotoxicity following cyclophosphamide therapy.

Minako Katayama1, Yukihiro Imai, Hisako Hashimoto, Masayuki Kurata, Kenichi Nagai, Koichi Tamita, Shigefumi Morioka, Yutaka Furukawa.   

Abstract

A 59-year-old male with an abdominal mass that showed a diffuse large B cell lymphoma underwent extirpation of the tumor and chemotherapy. He subsequently received high-dose chemotherapy containing cyclophosphamide (1.5 g/m(2)/day x 2 days), followed by autologous peripheral blood stem cell transplantation. He developed congestive heart failure 5 days after administration of cyclophosphamide. His electrocardiogram showed extremely low voltage with ST segment change and echocardiogram showed diffusely increased left ventricular wall thickness, an increase in myocardial echogenicity, pericardial effusion, and generally decreased systolic function. Congestive heart failure progressed rapidly and he died the following day. Post-mortem examination of the heart revealed myocardial hemorrhage, yellowish brown pericardial effusion, and fibrinous pericarditis. His liver was atrophic and focal necrosis was observed histologically. Cyclophosphamide-induced cardiotoxicity occurred, even though the patient had both shown normal cardiac function before high-dose chemotherapy and had received a lower dose of cyclophosphamide. Concomitant administration of cytarabine might have affected his liver function and there might have been interaction between the drugs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19782276     DOI: 10.1016/j.jjcc.2009.01.006

Source DB:  PubMed          Journal:  J Cardiol        ISSN: 0914-5087            Impact factor:   3.159


  16 in total

1.  Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

Authors:  Juan Carlos Plana; Maurizio Galderisi; Ana Barac; Michael S Ewer; Bonnie Ky; Marielle Scherrer-Crosbie; Javier Ganame; Igal A Sebag; Deborah A Agler; Luigi P Badano; Jose Banchs; Daniela Cardinale; Joseph Carver; Manuel Cerqueira; Jeanne M DeCara; Thor Edvardsen; Scott D Flamm; Thomas Force; Brian P Griffin; Guy Jerusalem; Jennifer E Liu; Andreia Magalhães; Thomas Marwick; Liza Y Sanchez; Rosa Sicari; Hector R Villarraga; Patrizio Lancellotti
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2014-10       Impact factor: 6.875

2.  Glutathione S-transferase P protects against cyclophosphamide-induced cardiotoxicity in mice.

Authors:  Daniel J Conklin; Petra Haberzettl; Ganapathy Jagatheesan; Shahid Baba; Michael L Merchant; Russell A Prough; Jessica D Williams; Sumanth D Prabhu; Aruni Bhatnagar
Journal:  Toxicol Appl Pharmacol       Date:  2015-04-10       Impact factor: 4.219

Review 3.  Cardiotoxicity of anticancer treatments: what the cardiologist needs to know.

Authors:  Michael S Ewer; Steven M Ewer
Journal:  Nat Rev Cardiol       Date:  2010-10       Impact factor: 32.419

Review 4.  The Role of Imaging with Cardiac Computed Tomography in Cardio-Oncology Patients.

Authors:  Barbora Pitekova; Sriram Ravi; Shimoli V Shah; Beata Mladosievicova; Stephen Heitner; Maros Ferencik
Journal:  Curr Cardiol Rep       Date:  2016-09       Impact factor: 2.931

Review 5.  Acute Cyclophosphamide Hemorrhagic Myopericarditis: Dilemma Case Report, Literature Review and Proposed Diagnostic Criteria.

Authors:  Subeer Wadia
Journal:  J Clin Diagn Res       Date:  2015-11-01

Review 6.  Evaluation and management of patients with heart disease and cancer: cardio-oncology.

Authors:  Joerg Herrmann; Amir Lerman; Nicole P Sandhu; Hector R Villarraga; Sharon L Mulvagh; Manish Kohli
Journal:  Mayo Clin Proc       Date:  2014-09       Impact factor: 7.616

Review 7.  Protective effects of curcumin on chemical and drug-induced cardiotoxicity: a review.

Authors:  Fatemeh Yarmohammadi; A Wallace Hayes; Gholamreza Karimi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-03-05       Impact factor: 3.000

8.  Inhibition of gene expression of organic cation/carnitine transporter and antioxidant enzymes in oxazaphosphorines-induced acute cardiomyopathic rat models.

Authors:  Mohamed M Sayed-Ahmed; Meshan Lafi Aldelemy; Mohamed M Hafez; Othman A Al-Shabanah
Journal:  Oxid Med Cell Longev       Date:  2012-05-30       Impact factor: 6.543

9.  Cyclophosphamide-Induced Cardiomyopathy: A Case Report, Review, and Recommendations for Management.

Authors:  Sumandeep Dhesi; Michael P Chu; Gregg Blevins; Ian Paterson; Loree Larratt; Gavin Y Oudit; Daniel H Kim
Journal:  J Investig Med High Impact Case Rep       Date:  2013-01-01

10.  A case of granulomatosis with polyangiitis complicated by cyclophosphamide toxicity and opportunistic infections: choosing between Scylla and Charybdis.

Authors:  Elena Ernst; Matthias Girndt; Rainer U Pliquett
Journal:  BMC Nephrol       Date:  2014-02-04       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.